Flecainide acetate prevents recurrence symptomatic paroxysmal supraventricular tachycardia Flecainide Supraventricular Tachycardia Study Group Oral acetate patients documented symptomatic paroxysmal supraventricular tachycardia PSVT double-blind placebo-controlled crossover trial design PSVT regular tachycardia beats/min evidence atrioventricular dissociation study considerable patient cooperation Patients qualifying phase open label flecainide dose-ranging phase blind fashion placebo treatment period symptomatic episodes PSVT end treatment period efficacy parameters flecainide superior Flecainide actuarial freedom symptomatic PSVT events placebo days patients recurrence symptomatic PSVT placebo phase patients recurrence flecainide phase median time first symptomatic PSVT event days placebo group days flecainide group Likewise interval attacks median days placebo days flecainide flecainide symptomatic PSVT heart rates beats/min placebo patients events placebo flecainide treatment phases 